Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes

Abstract

PurposeTo quantify willingness-to-pay (WTP) for reducing pill burden and dosing frequency among patients with type 2 diabetes mellitus (T2DM), and to examine the effect of dosing frequency and pill burden on likely medication adherence.Patients and methodsParticipants were US adults with T2DM on oral antihyperglycemic therapy. Each patient completed an online discrete-choice experiment (DCE) with eight choice questions, each including a pair of hypothetical medication profiles. Each profile was defined by reduction in average glucose (AG), daily dosing, chance of mild-to-moderate stomach problems, frequency of hypoglycemia, weight change, incremental risk of congestive heart failure (CHF), and cost. Patients were asked to rate their likely adherence to the profiles presented in each question. Choice questions were based on a predetermined experimental design. Choice data were analyzed using random-parameters logit. Likely treatment adherence was analyzed using a Heckman two-stage model.ResultsOf the 1,114 patients who completed the survey, 90 had lower dosing burden (<5 pills/day taken once/day or as needed) for all medications, and 1,024 had higher dosing burden (≥5 pills/day or more than once/day). Reduction in AG was valued most highly by patients. Hypoglycemia, chance of mild-to-moderate stomach problems, weight change, incremental risk of CHF, and daily dosing were less valued. Patients with higher current dosing burden had lower WTP for more convenient dosing schedules than patients with lower current dosing burden. Changes in dosing and cost impacted likely adherence. The magnitude of the impact of dosing on likely adherence was higher for patients with lower current dosing burden than for patients with higher current dosing burden.ConclusionPatients with T2DM were willing to pay for improvements in efficacy, side effects, and dosing. Patients’ WTP for more convenient dosing depended on current dosing burden, as did the effect of these attributes on likely adherence.

Medication-related factors of non adherence among patients with schizophrenia and bipolar disorder: Outcome of a cross-sectional survey in Maiduguri, North-eastern Nigeria

“…Similar outcomes have been documented in patients with HIV/AIDS who were on multiple antiretroviral medications and diabetics (Chesney, 2000;Hauber et al, 2013). The reasons that could be advanced for this include; the discomfort arising from the high 'pill burden' and the likelihood of more druginduced side effects due to multiple drug combinations.…”

Patients’ Preferences and Willingness to Pay for Solid Forms of Oral Medications—Results of the Discrete Choice Experiment in Polish Outpatients

“…They found that lower frequency of administration, shorter administration times, and milder dry cough appeared to improve stated adherence to antibiotic treatment of CF lung infections. Hauber et al [21] examined patients' preferences for attributes of oral antihyperglycemic agents among patients with type 2 diabetes mellitus, and in the other study, the effect of pill burden on dosing preferences, willingness to pay, and likely adherence among the same group of patients [22]. In the first two studies the most important measures of effectiveness were glucose control, medication-related cardiovascular risk, and weight gain, respectively.…”

Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence

“…In some disease states adherence is critical to survival rates, yet some degree of nonadherence is likely in a relatively high percentage of patients 54. Hauber et al found that patients are willing to pay for additional improvement not only in dosing frequency, but also in efficacy and side effects 55. In instances where long-term medical therapy is necessary to achieve desired outcomes, treatment efficacy can be compromised by suboptimal adherence, compliance, and persistence with the treatment in general.…”